Please login to the form below
Fosun Pharma
This page shows the latest Fosun Pharma news and features for those working in and with pharma, biotech and healthcare.
Kite bags $90m upfront in two Asian deals for lead CAR-T drug
Partners with Daiichi Sankyo and Fosun Pharma to focus in on non-Hodgkin lymphoma. ... In China, Kite has formed a joint venture with Chinese drugmaker Fosun Pharma to develop lead chimeric antigen receptor T cell (CAR-T) therapy axicabtagene ciloleucel
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2017
1, 600. Valeant. L'Oreal. Divestment. CeraVe AcneFree AMBI. 1, 300. Forward Pharma. ... 160. Kite Pharma. Fosun Pharma. Formation of a JV. Autologous T-cell therapies in cancer.
-
Unravelling China’s healthcare sector
Shanghai Fosun Pharma and Jiangsu Hengrui have both established R&D hubs in the US and partner with top research institutions for innovator drug research. . ... Jiangsu Hengrui Pharma and Hutchison Medi Pharma are running clinical trials in overseas
Deal Watch January 2017
Unravelling China’s healthcare sector
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Senior Account Director, Publications, Women’s health, Medical C...
-
Highly competitive salary
- Senior Account Director, Publications, Opthalmology, Medical Com...
-
Highly competitive salary
- Account Director, Publications, Opthalmology, Medical Communicat...
-
Highly competitive salary
- Senior Medical Writer, Rare diseases, Medical Communications age...
-
Highly competitive salary
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
-
Senior Account Manager
-
Salary TBC
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
-
Planner
-
Salary TBC
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Court rules on AZ and EU’s COVID-19 vaccine dispute
- BMS and Eisai to collaborate in deal worth up to $3.1bn
- BMS’s oral AML therapy Onureg receives EU approval
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
- Breaking Down the Wall: Blockchain in Healthcare and Pharma
- Building Better Patient Advocates Through Authentic Partnerships
- Virgo Health makes two hires to leadership team
- Hanover Health appoints Aleksandra Lugović as an associate director
- GSK aims for £33bn in sales by 2031 as CEO Walmsley lays out ten-year strategy
- Biogen plans confirmatory trial as FDA documents show struggle over Aduhelm approval
- Biogen discontinues clinical development of anti-tau antibody for Alzheimer’s disease
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- BMS and Eisai to collaborate in deal worth up to $3.1bn
- Diversity and inclusion in clinical trials
- BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- Numbers, navigation, and narratives: digital storytelling in medical communications
- Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
- Is this common data mistake killing your digital patient recruitment?
- Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
- The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
- By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
